Loading...
Please wait, while we are loading the content...
Similar Documents
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy
| Content Provider | Scilit |
|---|---|
| Author | Mottok, Anja Jurinovic, Vindi Farinha, Pedro Rosenwald, Andreas Leich, Ellen Ott, German Horn, Heike Klapper, Wolfram Boesl, Michael Hiddemann, Wolfgang Steidl, Christian Connors, Joseph M. Sehn, Laurie H. Gascoyne, Randy D. Hoster, Eva Weigert, Oliver Kridel, Robert |
| Copyright Year | 2018 |
| Description | Key Points High expression of FOXP1 predicts adverse FFS in patients with FL treated with immunochemotherapy. FOXP1 high and low expressors differ in specific gene mutations and gene expression changes. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757687/pdf |
| Ending Page | 235 |
| Page Count | 10 |
| Starting Page | 226 |
| DOI | 10.1182/blood-2017-08-799080 |
| Journal | Blood |
| Issue Number | 2 |
| Volume Number | 131 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2018-01-11 |
| Access Restriction | Open |
| Subject Keyword | Hematology Gene Expression Biomarker Rituximab Follicular Ffs Foxp1 Immunochemotherapy Expressors Journal: Blood (Vol- 61, Issue- 2) |
| Content Type | Text |
| Resource Type | Article |